Cargando…

Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence

Cellular senescence is an irreversible side effect of some pharmaceuticals which can contribute to tissue degeneration. OBJECTIVE: To determine whether pharmaceutical glucocorticoids induce senescence in tenocytes. METHODS: Features of senescence (β-galactosidase activity at pH 6 (SA-β-gal) and acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Poulsen, Raewyn C, Watts, Anna C, Murphy, Richard J, Snelling, Sarah J, Carr, Andrew J, Hulley, Philippa A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078757/
https://www.ncbi.nlm.nih.gov/pubmed/23727633
http://dx.doi.org/10.1136/annrheumdis-2012-203146
_version_ 1782323790189953024
author Poulsen, Raewyn C
Watts, Anna C
Murphy, Richard J
Snelling, Sarah J
Carr, Andrew J
Hulley, Philippa A
author_facet Poulsen, Raewyn C
Watts, Anna C
Murphy, Richard J
Snelling, Sarah J
Carr, Andrew J
Hulley, Philippa A
author_sort Poulsen, Raewyn C
collection PubMed
description Cellular senescence is an irreversible side effect of some pharmaceuticals which can contribute to tissue degeneration. OBJECTIVE: To determine whether pharmaceutical glucocorticoids induce senescence in tenocytes. METHODS: Features of senescence (β-galactosidase activity at pH 6 (SA-β-gal) and active mammalian/mechanistic target of rapamycin (mTOR) in cell cycle arrest) as well as the activity of the two main pathways leading to cell senescence were examined in glucocorticoid-treated primary human tenocytes. Evidence of senescence-inducing pathway induction in vivo was obtained using immunohistochemistry on tendon biopsy specimens taken before and 7 weeks after subacromial Depo-Medrone injection. RESULTS: Dexamethasone treatment of tenocytes resulted in an increased percentage of SA-βgal-positive cells. Levels of phosphorylated p70S6K did not decrease with glucocorticoid treatment indicating mTOR remained active. Increased levels of acetylated p53 as well as increased RNA levels of its pro-senescence effector p21 were evident in dexamethasone-treated tenocytes. Levels of the p53 deacetylase sirtuin 1 were lower in dexamethasone-treated cells compared with controls. Knockdown of p53 or inhibition of p53 activity prevented dexamethasone-induced senescence. Activation of sirtuin 1 either by exogenous overexpression or by treatment with resveratrol or low glucose prevented dexamethasone-induced senescence. Immunohistochemical analysis of tendon biopsies taken before and after glucocorticoid injection revealed a significant increase in the percentage of p53-positive cells (p=0.03). The percentage of p21-positive cells also tended to be higher post-injection (p=0.06) suggesting glucocorticoids activate the p53/p21 senescence-inducing pathway in vivo as well as in vitro. CONCLUSION: As cell senescence is irreversible in vivo, glucocorticoid-induced senescence may result in long-term degenerative changes in tendon tissue.
format Online
Article
Text
id pubmed-4078757
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40787572014-07-10 Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence Poulsen, Raewyn C Watts, Anna C Murphy, Richard J Snelling, Sarah J Carr, Andrew J Hulley, Philippa A Ann Rheum Dis Basic and Translational Research Cellular senescence is an irreversible side effect of some pharmaceuticals which can contribute to tissue degeneration. OBJECTIVE: To determine whether pharmaceutical glucocorticoids induce senescence in tenocytes. METHODS: Features of senescence (β-galactosidase activity at pH 6 (SA-β-gal) and active mammalian/mechanistic target of rapamycin (mTOR) in cell cycle arrest) as well as the activity of the two main pathways leading to cell senescence were examined in glucocorticoid-treated primary human tenocytes. Evidence of senescence-inducing pathway induction in vivo was obtained using immunohistochemistry on tendon biopsy specimens taken before and 7 weeks after subacromial Depo-Medrone injection. RESULTS: Dexamethasone treatment of tenocytes resulted in an increased percentage of SA-βgal-positive cells. Levels of phosphorylated p70S6K did not decrease with glucocorticoid treatment indicating mTOR remained active. Increased levels of acetylated p53 as well as increased RNA levels of its pro-senescence effector p21 were evident in dexamethasone-treated tenocytes. Levels of the p53 deacetylase sirtuin 1 were lower in dexamethasone-treated cells compared with controls. Knockdown of p53 or inhibition of p53 activity prevented dexamethasone-induced senescence. Activation of sirtuin 1 either by exogenous overexpression or by treatment with resveratrol or low glucose prevented dexamethasone-induced senescence. Immunohistochemical analysis of tendon biopsies taken before and after glucocorticoid injection revealed a significant increase in the percentage of p53-positive cells (p=0.03). The percentage of p21-positive cells also tended to be higher post-injection (p=0.06) suggesting glucocorticoids activate the p53/p21 senescence-inducing pathway in vivo as well as in vitro. CONCLUSION: As cell senescence is irreversible in vivo, glucocorticoid-induced senescence may result in long-term degenerative changes in tendon tissue. BMJ Publishing Group 2014-07 2013-06-01 /pmc/articles/PMC4078757/ /pubmed/23727633 http://dx.doi.org/10.1136/annrheumdis-2012-203146 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Basic and Translational Research
Poulsen, Raewyn C
Watts, Anna C
Murphy, Richard J
Snelling, Sarah J
Carr, Andrew J
Hulley, Philippa A
Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence
title Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence
title_full Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence
title_fullStr Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence
title_full_unstemmed Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence
title_short Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence
title_sort glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence
topic Basic and Translational Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078757/
https://www.ncbi.nlm.nih.gov/pubmed/23727633
http://dx.doi.org/10.1136/annrheumdis-2012-203146
work_keys_str_mv AT poulsenraewync glucocorticoidsinducesenescenceinprimaryhumantenocytesbyinhibitionofsirtuin1andactivationofthep53p21pathwayinvivoandinvitroevidence
AT wattsannac glucocorticoidsinducesenescenceinprimaryhumantenocytesbyinhibitionofsirtuin1andactivationofthep53p21pathwayinvivoandinvitroevidence
AT murphyrichardj glucocorticoidsinducesenescenceinprimaryhumantenocytesbyinhibitionofsirtuin1andactivationofthep53p21pathwayinvivoandinvitroevidence
AT snellingsarahj glucocorticoidsinducesenescenceinprimaryhumantenocytesbyinhibitionofsirtuin1andactivationofthep53p21pathwayinvivoandinvitroevidence
AT carrandrewj glucocorticoidsinducesenescenceinprimaryhumantenocytesbyinhibitionofsirtuin1andactivationofthep53p21pathwayinvivoandinvitroevidence
AT hulleyphilippaa glucocorticoidsinducesenescenceinprimaryhumantenocytesbyinhibitionofsirtuin1andactivationofthep53p21pathwayinvivoandinvitroevidence